Modified miR-15a has therapeutic potential for improving treatment of advanced stage colorectal cancer through inhibition of BCL2, BMI1, YAP1 and DCLK1
Metrics: PDF 450 views | HTML 1390 views | ?
Andrew Fesler1, Hua Liu1 and Jingfang Ju1
1Department of Pathology, School of Medicine, Stony Brook University, Stony Brook, NY 11794, USA
Jingfang Ju, email: email@example.com
Keywords: 5-fluorouracil; miR-15a; colorectal cancer; chemoresistance; modified miRNA
Abbreviations: CSC, colon cancer stem cells; CLL, chronic lymphocytic leukemia; TCGA, The Cancer Genome Atlas; TS, thymidylate synthase
Received: October 10, 2017 Accepted: December 08, 2017 Published: December 19, 2017
Despite advances in colon cancer treatments, resistance and recurrence remain a significant challenge in treating patients. Novel therapeutic strategies are in urgent need to overcome resistance and improve patient outcomes. MicroRNA based therapeutics have potential to help combat resistance. In this study, we have shown that low miR-15a expression correlates with poor patient prognosis. We have demonstrated the therapeutic potential of miR-15a in colon cancer. miR-15a inhibits several important genes (BCL2, BMI1, YAP1 and DCLK1), decreasing cancer progression and resistance. Additionally, by replacing uracil in miR-15a with 5-fluorouracil, we created a novel miR-15a mimic with enhanced therapeutic potential. This mimic maintains target specificity and is more potent than unmodified miR-15a in vitro and inhibits colon tumor metastasis in vivo. This mimic has great potential for therapeutic development for treating colon cancer patients. This novel modification has potential to advance the development of other microRNA based therapeutics beyond miR-15a.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.